A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 700mg BID plus ritonavir 100mg BID Versus Lopinavir/ritonavir 400mg/100mg BID when Administered in Combination with the Abacavir/Lamivudine 600mg/300mg Fixed-Dose Combination Tablet QD in Antiretroviral-Nave HIV-1 Infected Adults Over 48 Weeks

Registry ID

EUCTR2004-000060-27

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

GLAXO SMITHKLINE

Start date

2004-06-30

Completion date

2007-11-27

Last update

2026-08-16

Conditions

• HIV Infection

Summary

HIV Infection

Locations

• , , Italy

Related clinical trials

• Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
• Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma
• Colchicine to Reduce Coronary Artery Inflammation in People With HIV
• Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
• Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
• Dental Management of Patients With HIV in Pays de la Loire

View on source registry